



**Ridge Diagnostics, Inc. Presents
Clinical Data on Blood Test for Depression
At American Psychiatric Association Annual Meeting**

*San Diego, CA May 20, 2009 –Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from clinical studies for its first-in-class, proprietary blood test for Major Depressive Disorder (MDD), will be presented during a poster session entitled *Multianalyte Biomarker Blood Test to Aid in Diagnosis, Treatment and Management of Major Depressive Disorder*, at the American Psychiatric Association Annual Meeting, May 20, 2009.*

The blood test, for the first time, provides clinicians with biological information derived from physiological changes associated with MDD. By adding an objective, biological basis, the blood test results are intended to augment the paradigm used for neuropsychiatric diagnosis and patient management, primarily clinical interviews. The test utilizes immunoassay technology and a novel diagnostic method called Biomarker Hypermapping. The Hypermap uses multiple markers from a proprietary human biomarker library, translation medicine studies, iterative disease profiling and interrelated algorithms to achieve diagnostic values and to stratify patients.

“We are pleased to present this clinically important blood test to the psychiatric community at the APA meeting,” stated Stan Sewitch, President and CEO of Ridge. “We believe the assay results provide an objective adjunct to a patient’s diagnosis and management, while at the same time providing the research community with a valuable tool for optimization of studies.”

The poster will be presented by Dr. Perry Renshaw, Chief Medical Officer of Ridge Diagnostics and Director of Magnetic Resonance, Utah Brain Institute, and Professor of Psychiatry, University of Utah School of Medicine.

Ridge Diagnostics, Inc. is a neurodiagnostic company commercializing a breakthrough, first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company’s products are derived from a proprietary Human Biomarker Library and Hyper-Mapping™ technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic platform. Ridge Diagnostics testing services are provided through its CLIA certified laboratory in North Carolina, and is developing a kit version for future distribution. The company is located in San Diego, CA and Research Triangle Park, NC.

Contact: Lonna J Williams, CCO
877-743-4301
www.ridgedx.com